Meeting
2022 ASCO Gastrointestinal Cancers Symposium
Indirect treatment comparison of futibatinib with chemotherapy and pemigatinib in cholangiocarcinoma with FGFR2 fusions/rearrangements.
Authors
Mitesh J. Borad
Mayo Clinic, Phoenix, AZ
Mitesh J. Borad , Abigail Paine , Volker Wacheck , Yaohua He , Reza Kazerooni , Tehseen Salimi , John A. Bridgewater
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Track
Pancreatic Cancer,Hepatobiliary Cancer,Neuroendocrine/Carcinoid,Small Bowel Cancer
Sub Track
Therapeutics
DOI
10.1200/JCO.2022.40.4_suppl.440
Abstract #
440
Poster Bd #
C6
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Gastrointestinal Cancers Symposium
First-308: Phase III study of tinengotinib versus physician's choice in patients with FGFR-altered, chemotherapy- and FGFR inhibitor–refractory/relapsed cholangiocarcinoma.
First Author: Milind M. Javle
Poster
2024 ASCO Gastrointestinal Cancers Symposium
FOENIX-CCA4: A phase 2 study of futibatinib 20 mg and 16 mg in patients with advanced cholangiocarcinoma (CCA) and fibroblast growth factor receptor 2 (FGFR2) fusions/rearrangements.
First Author: Teresa Macarulla
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Gunagratinib, a highly selective irreversible FGFR inhibitor, in patients with previously treated locally advanced or metastatic cholangiocarcinoma harboring FGFR pathway alterations: A phase IIa dose-expansion study.
First Author: Ye Guo
Poster
2022 ASCO Gastrointestinal Cancers Symposium
Emerging treatments for advanced cholangiocarcinoma: Addressing the knowledge gap.
First Author: Elizabeth J Heller